In this issue:
Acute pancreatitis augments PDAC risk
Chemotherapy with FOLFIRINOX for locally advanced PDAC
Laparoscopy for resectable and borderline resectable pancreatic cancer
ctDNA measurements predicting clinical outcomes and tracking progression
Clinical significance of ctDNA analysis by metastatic sites
Bariatric surgery reduces the risk of pancreatic cancer
Genomic biomarkers and pancreatic cancer risk
Adjuvant chemotherapy for PDAC after neoadjuvant chemotherapy
Second-line therapy in PDAC for germline BRCA1-2 pathogenic variants
Please login below to download this issue (PDF)